 Spironolactone
"Spironolactone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
| Descriptor ID |
D013148
|
| MeSH Number(s) |
D02.540.679 D04.210.500.745.745.855
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Spironolactone".
Below are MeSH descriptors whose meaning is more specific than "Spironolactone".
This graph shows the total number of publications written about "Spironolactone" by people in this website by year, and whether "Spironolactone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 1 | 2 | | 2000 | 1 | 0 | 1 | | 2001 | 1 | 2 | 3 | | 2003 | 0 | 1 | 1 | | 2004 | 1 | 2 | 3 | | 2005 | 2 | 0 | 2 | | 2007 | 1 | 1 | 2 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2016 | 0 | 2 | 2 | | 2019 | 4 | 1 | 5 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Spironolactone" by people in Profiles.
-
Cattani VB, Jalil EM, Eksterman L, Torres T, Wagner Cardoso S, Castro CRV, Monteiro L, Wilson E, Bushman L, Anderson P, Veloso VG, Grinsztejn B, Estrela R. Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions. Clin Pharmacokinet. 2023 07; 62(7):1031-1041.
-
Cattani VB, Jalil EM, Eksterman L, Torres T, Cardoso SW, Castro CRV, Monteiro L, Wilson E, Bushman L, Anderson P, Veloso VG, Grinsztejn B, Estrela R. Impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics: a nested drug-drug interaction study in a cohort of Brazilian transgender women using HIV pre-exposure prophylaxis. J Antimicrob Chemother. 2022 09 30; 77(10):2729-2736.
-
Yu Y, Guan W, Masoudi FA, Wang B, He G, Spertus JA, Lu Y, Krumholz HM, Li J. Hospital Variation of Spironolactone Use in Patients Hospitalized for Heart Failure in China-The China PEACE Retrospective Heart Failure Study. J Am Heart Assoc. 2022 10 04; 11(19):e026300.
-
Beldhuis IE, Myhre PL, Bristow M, Claggett B, Damman K, Fang JC, Fleg JL, McKinlay S, Lewis EF, O'Meara E, Pitt B, Shah SJ, Vardeny O, Voors AA, Pfeffer MA, Solomon SD, Desai AS. Spironolactone in Patients With Heart?Failure, Preserved Ejection Fraction, and Worsening Renal Function. J Am Coll Cardiol. 2021 03 09; 77(9):1211-1221.
-
Raman SV, Hor KN, Mazur W, Cardona A, He X, Halnon N, Markham L, Soslow JH, Puchalski MD, Auerbach SR, Truong U, Smart S, McCarthy B, Saeed IM, Statland JM, Kissel JT, Cripe LH. Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial. J Am Heart Assoc. 2019 10; 8(19):e013501.
-
Lyon C, Utter B, DeSanto K. How effective is spironolactone for treating resistant hypertension? J Fam Pract. 2019 06; 68(5):E11-E13.
-
Merrill M, Sweitzer NK, Lindenfeld J, Kao DP. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. JACC Heart Fail. 2019 03; 7(3):228-238.
-
Nowak KL, Gitomer B, Farmer-Bailey H, Wang W, Malaczewski M, Klawitter J, You Z, George D, Patel N, Jovanovich A, Chonchol M. Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial. Am J Kidney Dis. 2019 08; 74(2):213-223.
-
Ravi SJ, Cree-Green M. Use of Successive Pharmacologic Hormone Suppression Testing for a Severe Presentation of Adolescent Polycystic Ovarian Syndrome: A Case Report. J Investig Med High Impact Case Rep. 2019 Jan-Dec; 7:2324709619850215.
-
Bristow MR, Sharma K, Assmann SF, Linas S, Gersh BJ, Grady C, Rice MM, Singh S, Boineau R, McKinlay SM, Greenberg BH. Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT. Eur J Heart Fail. 2017 04; 19(4):457-465.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|